We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Neuren Pharmaceuticals has announced that physicians from Madigan Army Medical Center will conduct an investigator-initiated Phase II trial to determine the safety and efficacy of Glypromate in reducing brain injury caused by out-of-hospital cardiac arrest.
A joint study between Karolinska Institutet in Sweden and Makerere University in Uganda has produced important findings on how the malaria parasite conceals itself in the placenta.
Australian pharmaceutical company Virax has filed a clinical trials application with the South African Medicines Control Council for approval to conduct a Phase I/IIa trial of its VIR201 HIV vaccine.
Strides Arcolab Ltd and Haw Par Healthcare, Singapore have entered into a share purchase agreement, which provides for Strides Singapore Pte Ltd (an indirect wholly owned subsidiary of the company) to acquire 100 per cent of Drug Houses of Australia (Asia) Pvt Ltd., Singapore (DHA) for a consideration of approximately Singapore $19.7 million, which was arrived at on a willing-buyer and willing-seller basis.
Bavarian Nordic A/S announced that its production facility in Kvistgård has been granted Manufacturing Authorisation according to the Medicines Act by the Danish Medicines Agency (Laegemiddelstyrelsen).
BioPharma, Inc. announced that Roche has discontinued its involvement in the development of daclizumab in asthma, which both companies had been co-developing since 2004.
MSD India, a wholly owned subsidiary of Merck & Co. Inc., launched their latest anti fungal drug, Cancidas IV (caspofugin acetate 50mg/ 70mg), in the Indian pharmaceutical market.
Barr Pharmaceuticals, Inc. said that is was evaluating the competing bid announced by Actavis Group to purchase PLIVA d.d., based in Zagreb, Croatia for $2.5 billion, or HRK 795.
News that Taiwan intends to amend local IP laws to allow for patented drugs manufactured locally to be exported to poorer countries appears to be aimed at building a revenue model into the manufacture in Taiwan of generic Tamiflu under so-called 'compulsory license.'